hematologic malignancies

Research Reports

Belief in Research, Religious Coping, and Willingness to Participate in Clinical Trials Among African American Patients With Hematologic Malignancies: A Pilot Study

02/06/2023

Marjorie E Petty, PhD, MSN

Cynthia Chernecky, PhD, RN, AOCN, FAAN

Irina Shishkina, BSN

Nita Maihle, PhD

Jean Pawl, PhD, RN, OCN, CNE

Jennifer L Waller, PhD

Lufei Young, PhD, RN, APRN-NP

Julie Zadinsky, PhD, MSS, RN, CIP

Petty et al evaluated the belief in research, religious coping, and willingness to participate in clinical trials by African American patients with hematologic malignancies. The basis for their exploration is that, while the AA population has...

Petty et al evaluated the belief...

02/06/2023

Journal of Clinical Pathways

News

Acalabrutinib Improves PFS and OS Over Other First-Line Regimens in CLL

02/16/2021

Journal of Clinical Pathways

FDA Alerts

FDA Approves Selinexor in Combination With Bortezomib and Dexamethasone for MM

12/18/2020

Journal of Clinical Pathways

Sponsored

Special Report

Product Perspectives: Brukinsa (Zanubrutinib) for Mantle Cell Lymphoma (Sponsored)

12/17/2020

This article was developed by HMP with support from BeiGene.   

This article was developed by...

12/17/2020

Journal of Clinical Pathways

Videos

HCRU, Costs With CAR-T Therapy Compared to Transplantation for DLBCL

12/17/2020

Karl Kilgore, PhD, discusses study results that showed greater HCRU and costs with CAR-T therapy than transplantation for patients with relapsed/refractory DLBCL.

Karl Kilgore, PhD, discusses...

12/17/2020

Journal of Clinical Pathways

Videos

Real-World Biomarker Testing, Treatment Patterns in CLL/SLL

12/17/2020

Anthony Mato, MD, discusses prognostic biomarker testing, treatment practices, and outcomes among patients with CLL in the clinical practice setting, using the informCLL prospective registry.

Anthony Mato, MD, discusses...

12/17/2020

Journal of Clinical Pathways

Conference Coverage

Cost-Effectiveness Comparison of BTK Inhibitors for MCL

12/09/2020

Journal of Clinical Pathways

Conference Coverage

Real-World Toxicity and Tolerability of Ibrutinib for CLL or SLL

12/09/2020

Journal of Clinical Pathways

Conference Coverage

Comparison of HCRU and Costs Associated With Treatments for Relapsed/Refractory DLBCL

12/06/2020

HCRU and costs associated with CAR-T therapy were greater than transplantation for DLBCL and cost offsets before and after the procedures provide useful insight for treatment planning.

HCRU and costs associated with...

12/06/2020

Journal of Clinical Pathways

Conference Coverage

Enasidenib Effective for Relapsed/Refractory IDH2-Mutated AML in Real-World Setting

12/06/2020

Results from a real-world study confirm the effectiveness of first-line enasidenib therapy for patients with relapsed/refractory IDH2-mutated AML outside of the trial setting.

Results from a real-world study...

12/06/2020

Journal of Clinical Pathways